<DOC>
	<DOCNO>NCT00281125</DOCNO>
	<brief_summary>This open-label , two-arm , multicenter Phase IA/II dose-escalation study PTK787 combination Pemetrexed alone ( Cohort 1 ) Pemetrexed Cisplatin ( Cohort 2 ) . This study design determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) PTK787 administer combination Pemetrexed Pemetrexed Cisplatin , characterize safety , tolerability , biologic activity , PK profile PTK787 adult patient advance non-small cell lung cancer mesotheliomas .</brief_summary>
	<brief_title>Phase I/II Trial PTK787 Pemetrexed With Without Cisplatin Lung Cancer</brief_title>
	<detailed_description>This open-label , two-arm , multicenter Phase IA/II dose-escalation study PTK787 combination Pemetrexed alone ( Cohort 1 ) Pemetrexed Cisplatin ( Cohort 2 ) . This study design determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) PTK787 administer combination Pemetrexed Pemetrexed Cisplatin , characterize safety , tolerability , biologic activity , PK profile PTK787 adult patient advance non-small cell lung cancer mesotheliomas . In cohort 1 , PTK787 administer orally every 12 hour day 2-42 42-day cycle . In addition , Pemetrexed administer day 1 22 . In cohort 2 , PTK787 administer orally every 12 hour day 2-42 42 day cycle . In addition , Pemetrexed administer day 1 22 . Thirty minute Pemetrexed administration , Cisplatin infuse day 1 22 . In current study , initially patient treat Cohort 1 ( Pemetrexed + PTK787 ) . Once MTD determination make cohort ( PTK787 escalate maximum dose 750 mg Q12h enrollment begin Cohort 2 . At MTD dose , cohort expand minimum 20 patient determine additional safety combination .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Patients advance nonsmall cell lung cancer ( nonsquamous variety advance mesotheliomas Patients advance solid tumor refractory standard treatment and/or standard treatment available patient Nonsmall cell carcinoma squamous variety Patients uncontrolled brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Pleural Mesothelioma</keyword>
</DOC>